At the news
? NEUTRALIMPACT 3/10 8-K filed Apr 7, 2026 at 16:01 ET
Collegium Pharmaceutical announced the nomination of Michael Donovan to its board of directors and the retirement of director John Fallon at the 2026 Annual Meeting. Fallon's departure is part of board refreshment and not due to disagreement.
- Michael Donovan, former EY audit partner with life sciences expertise, nominated to board
- Dr. John Fallon to retire from board after serving since 2016
- No CEO/CFO departure or executive change involved
- Board refreshment cited as reason for transition
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access